Shares in Glaukos Corp. rose 10% in after-hours trading today following the company’s first quarter results.
The Aliso Viejo-based medical device maker reported that revenue increased 41% to $150.6 million, exceeding the $139.7 million expected by analysts.
Following earnings, Glaukos jumped 10% to $129 apiece after the market closed. They had ended regular trading at $116.96 per share and a $6.8 billion market cap (NYSE: GKOS).
“Our record first quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” Glaukos Chairman and Chief Executive Thomas Burns said in a statement.
Glaukos also raised guidance to $620 million to $635 million, up from the previous range of $600 million to $620 million.
